Online inquiry

IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15372MR)

This product GTTS-WQ15372MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD37 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001040031.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 951
UniProt ID P11049
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15372MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7126MR IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA FE 999302
GTTS-WQ4722MR IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BOS161721
GTTS-WQ11050MR IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MCLA-128
GTTS-WQ10419MR IVTScrip™ mRNA-Anti-IL17A, LY2439821(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY2439821
GTTS-WQ3212MR IVTScrip™ mRNA-Anti-CD70, ARGX-110(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ARGX-110
GTTS-WQ4914MR IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA C11D5.3 scFv-8A-F9Z CAR
GTTS-WQ1034MR IVTScrip™ mRNA-Anti-MET, ABBV-399(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABBV-399
GTTS-WQ14633MR IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SC0001-SCX
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW